2,920 Shares in AtriCure, Inc. (NASDAQ:ATRC) Bought by R Squared Ltd

R Squared Ltd acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,920 shares of the medical device company’s stock, valued at approximately $89,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Champlain Investment Partners LLC raised its stake in shares of AtriCure by 4.3% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock worth $78,253,000 after buying an additional 115,813 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of AtriCure by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company’s stock worth $43,291,000 after purchasing an additional 6,045 shares in the last quarter. State Street Corp grew its stake in shares of AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after purchasing an additional 63,002 shares during the period. Geode Capital Management LLC increased its holdings in shares of AtriCure by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock valued at $32,326,000 after purchasing an additional 32,676 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of AtriCure by 132.5% in the second quarter. Millennium Management LLC now owns 952,765 shares of the medical device company’s stock valued at $21,694,000 after purchasing an additional 543,023 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Performance

Shares of ATRC opened at $40.60 on Friday. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11. The company’s 50 day simple moving average is $34.54 and its 200 day simple moving average is $29.99. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -48.92 and a beta of 1.42. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. The business had revenue of $115.91 million for the quarter, compared to analysts’ expectations of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The business’s revenue was up 17.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.20) earnings per share. On average, sell-side analysts predict that AtriCure, Inc. will post -0.75 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ATRC shares. JPMorgan Chase & Co. reissued an “overweight” rating and set a $40.00 price target on shares of AtriCure in a research note on Tuesday, December 17th. UBS Group raised their price target on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group boosted their price objective on shares of AtriCure from $53.00 to $61.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Needham & Company LLC increased their price objective on shares of AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. Finally, Oppenheimer lifted their target price on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.38.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.